东阳光长江药业年度报告 2024

C O N T E N T S 2Corporate Structure3Financial Summary5Corporate Profile7History of Development10Chairman’s Statement15Highlights of the Year16Management Discussion and Analysis62Profiles of Directors, Supervisors and Senior Management78Report of the Board of Directors121Report of the Board of Supervisors125Corporate Governance Report161Independent Auditor’s Report174Consolidated Statement of Profit or Loss andother Comprehensive Income175Consolidated Statement of Financial Position177Consolidated Statement of Changes in Equity178Consolidated Cash Flow Statement180Notes to the Financial Statements317Definitions322Corporate Information The followings are the financial highlights for the year ended 31December 2024 (“this year”or the“Reporting Period”): Revenue of the Group in 2024 was RMB3,723.78 million,representing a decrease of 40.84% as compared with 2023. Basic and diluted earnings per share was RMB0.55 for the yearended 31 December 2024. The Board does not recommend the payment of final dividend forthe year ended 31 December 2024 (for the year ended 31 December2023: Nil). YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceuticalmanufacturing company that focuses on the development,manufacturing and sales of pharmaceutical products in thetherapeutic areas of anti-infection diseases, endocrine and metabolicdiseases and other diseases. It is the domestic pharmaceuticalmanufacturing platform of the HEC Group. The Company entered into China’s pharmaceutical industrythrough the establishment of its predecessor, Yichang ChangjiangPharmaceutical Co., Ltd., in 2001. Up to now, we have beenoperating for more than 23 years, and are in the leading position inthe domestic pharmaceutical industry in terms of pharmaceuticalsales performance and research and development capability. The Company was converted into a joint stock limited companyon 11 May 2015, and was listed on the Main Board of the HongKong Stock Exchange on 29 December 2015, with the stock code01558.HK. 01558.HK Since its establishment, the Company has always followed themotto of“serving the Chinese with higher standards”and has astrong industrial foundation and leading competitive edges in themanufacturing, marketing and sales of pharmaceutical products.As of 31 December 2024, the Company has 1,854 professionalsales staff across nationwide product distribution network. Kewei(Oseltamivir Phosphate), one of the Company’s core products, isthe first-line drug for clinical application of anti-influenza virus inChina with strong brand influence and continues to maintain thepremier position in the field of influenza. Oseltamivir Phosphatewas included in the National Essential Drug List (2018 Version) in2018. In 2020, Oseltamivir Phosphate continued to be included inthe Influenza treatment plan (2020 version) published by NationalHealth Commission. In 2023, Oseltamivir Phosphate continued to beincluded in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 Version)issued by the Ministry of Human Resources and Social Security of thePeople’s Republic of China. CORPORATE PROFILE In addition, the Company has built strategic cooperativepartnerships with various renowned pharmaceutical enterprises.The Company reached a strategic cooperative partnership withChina National Accord Medicines Corporation Ltd. (SZSE: 000028.SZ) and kicked-off its first operational project during the year of2018. The Company entered into a strategic cooperation frameworkagreement with Jointown Pharmaceutical Group Co., Ltd. (“JointownPharmaceutical”), pursuant to which the Company authorisedJointown Pharmaceutical as the exclusive general distribution agentfor its Kewei products to be sold through the OTC channel(s) withinthe PRC. The Company entered into a letter of intent with WuhanInstitute of Virology, Chinese Academy of Sciences* ( ), National Engineering Technology Research Centerfor Drugs of Emergency Prevention and Control* ( ) and Sunshine Lake Pharma Co., Ltd.* ( , previously known as ) (“Sunshine Lake Pharma”), pursuant to which, these parties willjointly establish a national military-civilian integrated collaborativeindustrialization platform for drugs of emergency prevention andcontrol cum national antiviral drug centre. The Company believesthat the abovementioned strategic cooperative partnershipswill bring favourable development prospects for the Company’sbusiness. T h e C o m p a n y i s c o m m i t t e d t o t h e i m p l e m e n t a t i o n o fprofessionalism, branding and differentiated development strategiesall along. The Company is committed to the establishment of aprofessional marketing team, a steady and innovative marketingoperation and a strategic integration of resources, in order tocreate brand characteristics and core competitiveness unique to“Pharm HEC”in the industry and create additional value for the vastpharmaceutical consumers and our partners. In the future, the Compan